OpGen Pivots to FinTech, Reports $4M Revenue from Listing Services

TL;DR

**OpGen's radical pivot to FinTech is a high-stakes gamble, showing early revenue but still bleeding cash, making it a speculative play.**

AI Summary

OPGEN INC (CFOR) reported a significant strategic shift from precision medicine to financial services and technology, marked by the deconsolidation of its infectious disease subsidiaries, Curetis and Ares Genetics, in November 2023. For the nine months ended September 30, 2025, the company generated $4,000,000 in total revenue, primarily from listing sponsorship services, a stark contrast to the $196,149 from product sales and laboratory services in the prior year. Net income for the nine months ended September 30, 2025, was $2,493,129, a decrease from $7,642,696 in the same period of 2024, largely due to one-time gains in 2024 from extinguishment of debt and impairment adjustments. Operating income for the nine months ended September 30, 2025, was $2,177,744, a substantial improvement from an operating loss of $4,076,510 in 2024. Cash and cash equivalents decreased significantly to $414,211 as of September 30, 2025, from $1,310,653 at December 31, 2024. The company's current assets increased to $5,523,096 from $2,649,227, driven by a substantial rise in accounts receivable to $4,043,838 from $29,258. OPGEN INC continues to operate virtually and is exploring additional financing arrangements with AEI Capital Ltd. to sustain operations, with the right to sell up to $3.0 million in common stock.

Why It Matters

This strategic pivot is a make-or-break moment for OpGen, shifting from a struggling biotech to an unproven financial services and technology player. For investors, the substantial increase in accounts receivable to $4,043,838 suggests new revenue streams are materializing, but the sharp decline in cash to $414,211 highlights ongoing liquidity concerns. Employees face a completely new operational focus, while former customers of its precision medicine solutions will need to seek alternatives. The broader market will watch if this drastic change can successfully reposition the company in a competitive financial technology landscape, especially given the involvement of AEI Capital Group with over $3.0 billion in assets under management.

Risk Assessment

Risk Level: high — The company has incurred significant losses from operations since inception and has negative operating cash flows, with cash and cash equivalents at only $414,211 as of September 30, 2025. The strategic shift to a new industry (financial services and technology) introduces substantial execution risk, as the company lacks a proven track record in this sector. Furthermore, the reliance on financing arrangements with AEI Capital Ltd. for future operations, including the right to sell up to $3.0 million in common stock, indicates ongoing dependence on external capital.

Analyst Insight

Investors should approach CFOR with extreme caution, recognizing the high-risk, high-reward nature of its strategic pivot. Monitor the company's ability to convert its substantial accounts receivable into cash and its progress in securing additional financing from AEI Capital Ltd. or other sources. This is a speculative investment, suitable only for those with a high-risk tolerance and a belief in the new management's ability to execute a complete business transformation.

Financial Highlights

debt To Equity

0.24

revenue

$4,000,000

operating Margin

54.44%

total Assets

$12,639,255

total Debt

$2,481,290

net Income

$2,493,129

eps

N/A

gross Margin

N/A

cash Position

$414,211

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $4,000,000 — Total Revenue (for the nine months ended September 30, 2025, primarily from listing sponsorship services, up from $196,149 in 2024)
• $2,493,129 — Net Income (for the nine months ended September 30, 2025, down from $7,642,696 in 2024)
• $414,211 — Cash and Cash Equivalents (as of September 30, 2025, a decrease from $1,310,653 at December 31, 2024)
• $4,043,838 — Accounts Receivable, net (as of September 30, 2025, a significant increase from $29,258 at December 31, 2024)
• $2,177,744 — Operating Income (for the nine months ended September 30, 2025, a substantial improvement from an operating loss of $4,076,510 in 2024)
• $3.0 million — Common Stock Sale Right (aggregate value of common stock OPGEN INC has the right to sell to AEI Capital Ltd.)
• 10,071,286 — Shares Outstanding (as of November 19, 2025)

Key Players & Entities

• OPGEN INC (company) — registrant
• Curetis N.V. (company) — former subsidiary
• Curetis GmbH (company) — former subsidiary
• Ares Genetics GmbH (company) — former wholly-owned subsidiary
• David E. Lazar (person) — former CEO, Chairman, and Director; current President
• AEI Capital Ltd. (company) — investor and strategic partner
• CapForce International Holdings Ltd. (company) — wholly-owned subsidiary for new business line
• Nasdaq Capital Market (regulator) — exchange where common stock is traded

FAQ

Risk Factors

• Dependence on Financing [high — financial]: The company's ability to sustain operations is dependent on securing additional financing, including the right to sell up to $3.0 million in common stock to AEI Capital Ltd. A failure to secure adequate funding could jeopardize ongoing operations.
• Virtual Operations [medium — operational]: The company continues to operate virtually. While this may reduce overhead, it could also present challenges in terms of collaboration, oversight, and potential operational inefficiencies.
• Significant Increase in Accounts Receivable [medium — financial]: Accounts receivable increased dramatically from $29,258 as of December 31, 2024, to $4,043,838 as of September 30, 2025. This substantial increase requires careful monitoring for collectability and could impact cash flow.
• Decreased Cash Position [high — financial]: Cash and cash equivalents decreased from $1,310,653 at December 31, 2024, to $414,211 as of September 30, 2025. This reduced liquidity necessitates the ongoing pursuit of financing.
• Unregistered Sales of Equity Securities [medium — regulatory]: The filing mentions 'Unregistered Sales of Equity Securities' as a section title. This suggests potential past or ongoing activities that may carry regulatory scrutiny or require specific disclosures.

Industry Context

OPGEN INC has undergone a significant strategic pivot from precision medicine to financial services and technology, specifically focusing on listing sponsorship services. This shift places it in a different competitive landscape, likely involving advisory firms and financial intermediaries. The industry trend towards specialized financial services and the increasing complexity of capital markets may create opportunities for companies offering such niche support.

Regulatory Implications

The company's reliance on equity financing, including the potential sale of up to $3.0 million in common stock, necessitates compliance with securities regulations. Disclosures regarding unregistered sales of equity securities, if applicable, are critical for maintaining regulatory compliance and investor confidence.

What Investors Should Do

1. Monitor Cash Burn and Financing
2. Evaluate Accounts Receivable Collectability
3. Assess Sustainability of Listing Sponsorship Revenue
4. Analyze Operating Expense Structure

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Period of significant revenue generation from listing sponsorship services and improved operating income, but decreased net income and cash position.
• 2024-12-31: As of December 31, 2024 — Represents the prior year-end balance sheet figures for comparison, showing a higher cash position and lower accounts receivable.
• 2023-11-01: Deconsolidation of Curetis and Ares Genetics — Marks the strategic shift away from precision medicine towards financial services and technology.

Glossary

Deconsolidation

The process of removing a subsidiary from a parent company's consolidated financial statements. (Key to understanding OPGEN's strategic shift away from its precision medicine subsidiaries.)

Listing sponsorship services

Services provided to companies seeking to list their securities on a stock exchange, often involving advisory and administrative support. (The primary source of revenue for OPGEN in the reported period, highlighting its new business focus.)

Accumulated deficit

The cumulative net losses of a company since its inception, offset by any net profits. (OPGEN has a substantial accumulated deficit of ($291,007,393) as of September 30, 2025, indicating a history of losses.)

Operating lease right-of-use assets

Assets recognized under accounting standards for leases, representing the right to use an asset over the lease term. (Represents a significant non-cash asset on the balance sheet, related to the company's operational infrastructure.)

Year-Over-Year Comparison

Compared to the prior year period, OPGEN INC has experienced a dramatic shift in its revenue profile, with total revenue for the nine months ended September 30, 2025, reaching $4,000,000 primarily from listing sponsorship services, a stark contrast to the $196,149 from product and laboratory services in 2024. While net income decreased from $7,642,696 to $2,493,129 due to one-time gains in the prior year, operating income saw a substantial improvement from a loss of $4,076,510 to an income of $2,177,744. However, cash reserves have dwindled significantly, and accounts receivable have surged, indicating a more precarious liquidity position despite improved operational profitability.

Key Financial Figures

• $0.01 — f the Company's common stock, par value $0.01 per share, were outstanding as of Novem
• $3.0 billion — pwide assets under management exceeding $3.0 billion (see Note 8). In conjunction with the t
• $5.0 million — eceived gross proceeds of approximately $5.0 million in 2024. The Company has cash and cash
• $0.4 — ompany has cash and cash equivalents of $0.4 414,211 million as of September 30, 202
• $3.0 million — tock having an aggregate value of up to $3.0 million. The purchase price for any shares sold

Filing Documents

• opgeninc_10q.htm (10-Q) — 940KB
• opgeninc_ex31-1.htm (EX-31.1) — 17KB
• opgeninc_ex32-1.htm (EX-32.1) — 8KB
• 0001829126-25-009312.txt ( ) — 4845KB
• opgn-20250930.xsd (EX-101.SCH) — 36KB
• opgn-20250930_cal.xml (EX-101.CAL) — 52KB
• opgn-20250930_def.xml (EX-101.DEF) — 157KB
• opgn-20250930_lab.xml (EX-101.LAB) — 272KB
• opgn-20250930_pre.xml (EX-101.PRE) — 231KB
• opgeninc_10q_htm.xml (XML) — 742KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

SIGNATURES

SIGNATURES 32 i INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this quarterly report, we refer to OpGen, Inc. as the "Company", "OpGen", "we", "our" or "us". All statements, other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words "believe", "may", "will", "estimate", "continue", "anticipate", "design", "intend", "expect" or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I Item 1A "Risk Factors" of our most recent annual report on Form 10-K. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our liquidity and working capital requirements, including our cash requirements over the next 12 months; our ability to execute upon and achieve the benefits of th

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements OpGen, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 414,211 $ 1,310,653 Accounts receivable, net 4,043,838 29,258 Inventory, net - - Prepaid expenses and other current assets 1,065,047 1,309,316 Total current assets 5,523,096 2,649,227 Property and equipment, net 966,231 1,079,275 Operating lease right-of-use assets 797,666 825,665 Investment in equity securities 5,000,000 5,000,000 Deferred offering costs - 6,269 Intangible assets, net 50,000 - Restricted cash 302,262 302,262 Total assets $ 12,639,255 $ 9,862,698 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 307,776 $ 245,196 Accrued compensation and benefits 25,444 62,907 Accrued liabilities 81,755 62,074 Short-term insurance financing 172,521 90,278 Current portion of operating lease liabilities 195,003 173,726 Total current liabilities 782,499 634,181 Operating lease liabilities, net of current portion 1,698,791 1,847,889 Total liabilities 2,481,290 2,482,070 Commitments and Contingencies (Note 9) Stockholders' equity: Series D Preferred stock, $ 0.01 par value; 10,000,000 shares authorized; 250 shares issued and outstanding at September 30, 2025 and December 31, 2024 2 2 Common stock, $ 0.01 par value; 100,000,000 shares authorized; 10,071,286 and 10,070,779 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 100,713 100,708 Additional paid-in capital 301,064,643 300,780,440 Accumulated deficit ( 291,007,393 ) ( 293,500,522 ) Total stockholders' equity 10,157,965 7,380,628 Total liabilities and stockholders' equity $ 12,639,255 $ 9,862,698 See accompanying notes to unaudited condensed

View Full Filing

View this 10-Q filing on SEC EDGAR